tbuckley/cabot-search huggingface dataset:
Clinical predictors of larynx preservation (LP) after multiagent concurrent chemoradiotherapy (MCCRT)
Authors: C. P. Rodriguez, D. J. Adelstein, L. Rybicki, J. P. Saxton, R. R. Lorenz, B. G. Wood, M. Strome, R. M. Esclamado, P. Lavertu, M. Carroll
Journal: Journal of Clinical Oncology (2007)

6075 Background: Identification of patients (pts) with larynx and hypopharynx (HP) squamous cell cancer (SCC) most likely to benefit from a LP strategy remains problematic. We retrospectively reviewed the Cleveland Clinic experience using MCCRT to identify potential clinical predictors for success. Methods: Definitive CCRT was considered appropriate for pts with locoregionally confined larynx or HP SCC except for those with cartilage invasion or laryngeal destruction. Cisplatin (20 mg/m2/day) and 5-FU (1,000 mg/m2/day) were given as continuous intravenous infusions on days 1–4 during the first and fourth weeks of either once or twice daily radiation. Laryngectomy was only performed for locally persistent or recurrent disease. Results: Between 1989 and 2006, 115 pts were treated; 87 (76%) were male, and 102 (89%) were white. The median age was 59 (range 31–77) years. The primary site was the HP in 46 pts (40%) , supraglottis in 50 (43%) and glottis in 19 (17%). Tumor was T1 in 4 (3%), T2 in 31 (27%), T3 in 42 (37%), T4 in 37 (32%), and TX in 1 (1%). Disease was stage II in 8 (7%), III in 34 (30%), and IV in 73 (63%). With a median follow up of 62 (range 5–195) months, the 5-year Kaplan-Meier projected local control rate without surgery is 82%. Residual primary site disease was found in only 5 pts after MCCRT. Primary site recurrence developed in 14 more pts. Surgical salvage was successful in 13 of these 19 pts (68%). The 5-year projected local control rate (including surgical salvage) is 94%. Late complications after successful LP included permanent tracheotomy in 3, and feeding tube dependence in 7 pts. For all 115 pts, the 5-year projected freedom from recurrence is 64%, overall survival 58% and laryngectomy-free survival 52%. Local control without surgery was more likely in pts with T1–2 compared to T3–4 tumors (97% vs. 75%, P=0.01), but was not predicted by age, race, tumor differentiation, primary site, nodal status, stage, radiation schedule (daily vs. twice daily), baseline hemoglobin, or continued smoking. Conclusions: This MCCRT regimen can be expected to result in successful LP in all clinical subsets of appropriately selected pts with larynx and HP SCC. Although local failure was more likely in pts with T3 or T4 tumors, it was infrequent, and subsequent surgical salvage was highly effective. No significant financial relationships to disclose.
Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS
Authors: Guillermo Garcia Manero, Luger Selina, Klimek Virginia, Cooper Maureen, Emmanuel C. Besa, James M. Rossetti, Richard Chao, Rachel Humphrey, Lewis R. Silverman
Journal: Blood (2013)
On Being a 21st Century Patient
Authors: Lois Snyder Sulmasy, Daniel P. Sulmasy
Journal: Annals of Internal Medicine (2016)

On Being a Patient15 March 2016On Being a 21st Century PatientLois Snyder Sulmasy, JD and Daniel P. Sulmasy, MD, PhDLois Snyder Sulmasy, JDFrom American College of Physicians, Philadelphia, Pennsylvania; University of Chicago, Chicago, Illinois.Search for more papers by this author and Daniel P. Sulmasy, MD, PhDFrom American College of Physicians, Philadelphia, Pennsylvania; University of Chicago, Chicago, Illinois.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-1975 Audio Reading - “On Being a 21st Century Patient” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "On Being A 21st Century Patient," by L. Snyder Sulmasy and D.P. Sulmasy. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I confess: I was anxious on the ride over. I would be seeing a new doctor.In a nicely appointed waiting room, with ample chairs, there was the usual paperwork to be done. Looking around, there were individuals just like me and some very different from me. One patient was doggedly staring at my legs. He made me a little uncomfortable, so I looked the other way. But, overall, I liked the atmosphere. It was a diverse practice.They treated the insured and the uninsured alike, with an eye toward affordability and transparent fees. It had not been hard to ... Author, Article, and Disclosure InformationAffiliations: From American College of Physicians, Philadelphia, Pennsylvania; University of Chicago, Chicago, Illinois.Corresponding Author: Lois Snyder Sulmasy, JD, Center for Ethics and Professionalism, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106; e-mail, [email protected]org.This article was published at www.annals.org on 2 February 2016. PreviousarticleNextarticle Advertisement Audio Reading - “On Being a 21st Century Patient” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "On Being A 21st Century Patient," by L. Snyder Sulmasy and D.P. Sulmasy. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 March 2016Volume 164, Issue 6Page: 446KeywordsBloodComputersConjunctivitisEmotionsExerciseMotivationResearch laboratoriesSmellTemperatureUpper respiratory tract infections ePublished: 15 March 2016 Issue Published: 15 March 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Bioethics Skill Sets Can Work, But It Would Take Moral Courage to Apply Them and Get Desired Results
Authors: Stephen Sodeke
Journal: The American Journal of Bioethics (2016)

In “Bioethicists Can and Should Contribute to Addressing Racism,” Danis, Wilson, and White (2016) discussed seven skill sets that bioethicists can use to contribute meaningfully in the effort to ad...
Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.
Authors: J. Kurtz, F. Hilpert, A. Dorum, A. Veillard, L. Elit, M. Buck, E. Petru, N. Reed, G. Scambia, N. Varsellona
Journal: Journal of Clinical Oncology (2010)

5031 Background: In the CALYPSO trial, carboplatin (C)-pegylated liposomal doxorubicin (PLD) demonstrated a superior therapeutic index (TI) versus C-paclitaxel (P) in patients (pts) with ROC >6 mo after 1st- or 2nd-line platinum-based therapy. The aim of this analysis was to evaluate efficacy and tolerability of C-based doublets in the subset of elderly pts (≥ 70 y). Methods: 976 pts with taxane-pretreated ROC were randomized between C-PLD [C AUC 5 IV + PLD 30 mg/m2 IV] d1 q4 wk, or C-P [C AUC 5 IV + P 175 mg/m2 IV] d1 q3 wk × ≥ 6 cycles. Results: 157 (16%) pts were ≥ 70 y: 71 in C-PLD arm (median age 74, range 70-82.4) and 86 in C-P arm (median age 73, range 70.2-82). Pts characteristics including geriatric parameters (body mass index, comorbidity) were well balanced between arms. The median PFS was 11.6 and 10.3 months in C-PLD and C-P arms, respectively. Elderly pts completed ≥ 6 planned cycles at the same rate as younger pts (82% C-PLD, 78% C-P). Myelosuppression did not differ with age. Nonhematologic toxicities are summarized in the Table. Compared to younger pts, elderly experienced less allergic reactions (5.8% vs. 14.0%, p=0.005), but significantly more grade > 2 neurotoxicity (24.7% vs. 15.6%, p=0.006). Conclusions: This subanalysis of the CALYPSO trial, the first reported for elderly ROC pts treated with C-based doublets, showed a similar TI for elderly pts versus younger pts. Overall, less hypersensitivity reactions and more neuropathy were observed in elderly versus younger pts. Based on these findings, C-PLD appears to be the more preferable treatment option in elderly ROC pts. Grade ≥ 2 nonhematologic toxicities Age < 70 Age ≥ 70 C-P (%)n=416 C-PLD (%)n=393 C-P (%)n=86 C-PLD (%)n=71 Alopecia 83.7 6.4 86.9 11.4 Sensory neuropathy 26.2 4.3 36.9 10 Allergy 21.4 6.1 7.1 4.3 Arthralgia/myalgia 19 4.3 22.1 2.9 Hand-foot syndrome 2.2 12 2.4 14.3 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough Schering-Plough
Characterization of prostate cancer treatment information quality obtained through Yahoo, Google, and Bing search engines.
Authors: D. Landau, J. Hajdenberg
Journal: Journal of Clinical Oncology (2010)

6047 Background: We characterized results of search engines to understand their informative value versus potential for misinformation. Methods: Using Search engines Google, Yahoo, and Bing, the term “prostate cancer treatment” was entered. 10 pages of unsponsored results were analyzed and divided into categories: medical-based information (MED), unapproved/potentially harmful therapies (UT), hospital/clinics practicing standard of care (StAD), and alternative therapy centers promoting nonstandard of care (NonStan). Sponsored results were identically categorized. Similarly, searches for breast, colon, and lung cancer were done to determine percentages of unapproved therapies. 100 unsponsored websites and 50 sponsored websites were reviewed. Results: 294 unsponsored and 174 sponsored sites were analyzed. MED included websites using level I-II evidence or pages providing news articles. Such websites included WebMD, UpToDate, CNN, etc. StAD were sites for hospitals, comprehensive cancer programs, or physicians promoting standard of care. NonStan included “naturalist physicians” or centers promoting first line therapies not recognized by NCCN guidelines, including HIFU and cryotherapy. UT included high-dose vitamins, enemas, selenium, and other cancer treatments with no additional information provided without upfront payment. The Table below summarizes the results. For breast, lung, and colon malignancies, the percentage of unapproved therapies was 2%, 3%, and 4%, respectively, in general searches, and 25%, 12%, and 25%, respectively, in sponsored advertisements. Conclusions: Whereas unsponsored searches provide useful information to patients with prostate cancer, it remains a potential source of misinformation or abuse in up to 17% of searches. For unknown reasons this potential is one order of magnitude greater than what we observed for other commonly diagnosed malignancies. Sponsored results should be ignored as the risk of misinformation approaches 75%. Unsponsored results % (n = 294) Sponsored results % (n = 174) MED 70 (206) 14 (24) StAD 12.5 (37) 11 (20) NonStan 5 (14) 26 (45) UT 12.5 (37) 49 (85) NonStan + UT 17.5 (51) 75 (130) No significant financial relationships to disclose.
Consent forms are unhelpful
Authors: I C M Paterson
Journal: BMJ (1995)

EDITOR,—I suspect that the case of an anaesthetist found guilty by the General Medical Council of an assault through lack of consent to his actions will precipitate the full range of emotions among doctors, from concern to outrage.1 The council may, however, have done the profession a favour in the troubled area of consent, which continues to languish in the era since the case of Sidaway v Governors of Bethlem Royal Hospital.2 In that case it was sufficient to show that other doctors (even a minority) would not …
My Physio App: better communication, understanding and results
Authors: Sallie Cowan
Journal: British Journal of Sports Medicine (2016)

Health and Fitness

Requires IOS 6.0 or more recent on Apple products. Requires Android 2.2 or more recent for Android products.

Web App: any web browser, Google Chrome preferred.

Free trial available for practices. App free for patients, practices/users pay a fee ranging from 9$/month (student) to $129/month (large practice with multiple locations).

Physio's and other health practitioners have struggled for years with stick figures and messy hand written exercise programmes. This is compounded by patients losing programmes and the difficulty of how to appropriately record the programme within your notes. MyPhysioApp neatly address's these issues and provides a great tool to continue to connect with your patient population long after they have left your rooms.

MyPhysioApp is an app that allows you to send exercise programmes directly to your client's mobile device. Choose from over 550 common exercises (eg, figure 1) with professional photos and videos, or if …
P56 Factor Xa inhibition suppresses thioacetamide induced liver fibrosis
Authors: A Dhar, Q Anstee, F Sadiq, A Levene, R Goldin, M Thursz
Journal: Gut (2010)

Introduction  In addition to its role in activating fibrinogen, thrombin mediates cellular activation of macrophages, platelets and hepatic stellate cells via the protease-activated receptor, PAR-1. Thrombin antagonists demonstrate anti-fibrotic properties. Factor Xa (FXa), a protease which is activated earlier in the coagulation cascade, promotes connective tissue growth factor, and activates fibroblasts via PAR receptors. Direct FXa inhibition has recently been shown to significantly reduce lung fibrosis, a paradigm for hepatic fibrosis, in a bleomycin mouse model. Specific inhibition of FXa may offer additional efficacy as an anti-fibrotic in models of chronic liver injury.  Aim  To evaluate the impact of FXa inhibition and thrombin antagonism on hepatic fibrosis using a thioacetamide (TAA) mouse model.  Method  45 C57BL/6J mice were administered TAA (300 mg/l) via drinking water for a period of 8 weeks to induce liver fibrosis. A subset of these animals were given Rivaroxaban, a direct FXa inhibitor (n=15), or Dagibatran, a direct thrombin antagonist (n=15). Both drugs were administered daily by oral gavage at doses to achieve prolongation of the prothrombin time. The remaining animals (n=15) received no anticoagulation, and acted as the control group. At 8 weeks livers were extracted and liver sections stained with picorsirus red and visually scored for fibrosis using an adapted Ishak Modified Histology Activity Index by a blinded histopathologist. Digital image analysis was performed to calculate the mean percentage area of fibrosis per section.  Results  In control mice the mean fibrosis score was 4.08 and the mean percentage area of fibrosis was 3.76%. In comparison mice treated with FXa inhibition had a mean fibrosis score of 2.46 (p=0.008) and mean percentage area of fibrosis of 2.02% (p=0.012). In contrast mice treated with thrombin inhibition had a mean fibrosis score of 3.25 (p=0.68 vs controls), and mean percentage area of fibrosis of 3.70% (p=0.68 vs controls). Factor Xa inhibition was significantly more effective than thrombin in reducing percentage area of fibrosis (p=0.031).  Conclusion  FXa inhibition significantly decreased the rate of hepatic fibrosis in a TAA model of liver fibrosis. It is likely that direct thrombin inhibition is less effective than FXa inhibition because thrombin inhibitors fail to block PAR-mediated stellate cell activation by FXa. FXa inhibition is a potential novel anti-fibrotic approach and warrants further investigation in human studies.
Changes in Arterial Access Site and Association With Mortality in the United Kingdom
Authors: Mamas A. Mamas, James Nolan, Mark A. de Belder, Azfar Zaman, Tim Kinnaird, Nick Curzen, Chun Shing Kwok, Iain Buchan, Peter Ludman, Evangelos Kontopantelis
Journal: Circulation (2016)

The transradial access (TRA) site has become the default access site for percutaneous coronary intervention in the United Kingdom, with randomized trials and national registry data showing reductions in mortality associated with TRA use. This study evaluates regional changes in access site practice in England and Wales over time, examines whether changes in access site practice have been uniform nationally and across different patient subgroups, and provides national estimates for the potential number of lives saved or lost associated with regional differences in access site practice.Using the British Cardiovascular Intervention Society database, we investigated outcomes for growth of TRA in different regions in England and Wales in 448 853 patients who underwent percutaneous coronary intervention from 2005 to 2012. Multiple logistic regression was used to quantify the effect of TRA on 30-day mortality and quantify lives saved and lost by differences in TRA adoption. TRA use increased from 14.0% to 58.6% in 417 038 PCI patients with large variations in different parts of the country. TRA was independently associated with a decreased risk of 30-day mortality (odds ratio=0.70; 95% confidence interval=0.66-0.74), with significant but small differences observed across different regions. The number of estimated lives saved was 450 (95% confidence interval=275-650), and we estimate that an additional 264 (95% confidence interval=153-399) lives would have been saved if TRA adoption were uniform nationally.TRA has become the dominant percutaneous coronary intervention approach in the United Kingdom, with a wide variation in different parts of the country. Changes in practice have contributed to mortality reductions, and inequalities have resulted in missed opportunities for further improvements.
<i>The Lost Felice</i>
Authors: Carrie A. Butt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Skin Uptake of 99mTc-HDP in a Case of Annular Elastolytic Giant Cell Granuloma
Authors: Maria del Val Gomez, Bernard Theillac, Sebastian Rizkallal Monzon, Berta Covadonga Lorente Castro, Jose Manuel Castro-Beiras
Journal: Clinical Nuclear Medicine (2016)

Sometimes unexpected extraosseous uptakes appear in a bone scintigraphy as a consequence of a wide spectrum of nonosseous disorders. Recognition of these findings is important to enhance the diagnostic value of bone scintigraphy. We report a case of intense bone scintigraphy cutaneous uptake due to elastolytic actinic giant cell granuloma (EAGCG). We present the case of a patient with intense extraosseous uptakes of 99mTc-HDP that appeared in a bone scintigraphy that was performed for lumbar pain.
AN INTEGRATIVE ANALYSIS TO IDENTIFY EPIGENETIC ABERRATIONS IN BASAL-LIKE BREAST CANCER CELL LINES
Authors: An Hendrix, Hannelore Denys, Geert Braems, Patrick Pauwels, Rudy Van den Broecke, Veronique Cocquyt, Wendy Westbroek, Marc Bracke, Olivier De Wever
Journal: Annals of Oncology (2010)
Growth Kinetics of Plasma Cell Myeloma2
Authors: Benjamin Drewinko, Raymond Alexanian
Journal: JNCI Journal of the National Cancer Institute (1977)

The plasma cell labeling index(ex) (LI) of 128 patients with multiple myeloma at various stages of disease was compared as a function of tumor mass load and length of treatment. No significant differences in LI were noted for patients with various degrees of tumor reduction. Patients observed during the first 3 months of treatment had significantly higher LI than did untreated patients and those studied after longer intervals. In vivo cell-cycle analysis of myeloma cells by the halving time of the grain-count method failed to establish the length of the cell cycle but defined the length of S+G2 phases as being longer than 60 hours. Similar studies conducted in vitro defined a shorter combined length of S+G2 phase. In 2 patients in whom continuous infusion with [3H] thymidine was performed, the generation time was established as 8 days. Both patients had similar initial LI (5.7 and 6.6) but different growth fractions (19 and 47%). The measured tumor mass doubling time was much longer than the calculated one, suggesting the presence of considerable intrinsic cell loss (83 and 47%). These observations were summarized by a hypothetical two-compartment model for the growth kinetics of multiple myeloma.
Chlorambucil-induced myoclonic seizures in an adult.
Authors: I LaDelfa, N Bayer, R Myers, V Hoffstein
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.12.1691 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 4067618 Chlorambucil-induced myoclonic seizures in an adult. I LaDelfaxI LaDelfaSearch for articles by this author , N BayerxN BayerSearch for articles by this author , R MyersxR MyersSearch for articles by this author , V HoffsteinxV HoffsteinSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.12.1691 PDF "Chlorambucil-induced myoclonic seizures in an adult.." Journal of Clinical Oncology, 3(12), pp. 1691–1692© 1985 by American Society of Clinical Oncology